Abivax S.A.: Form 20-F for the period ended Dec 31, 2025
Filed with the SEC on Mar 23, 2026 and accepted by EDGAR at Mar 23, 2026, 16:54 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 12 months2025-01-01 to 2025-12-31 | −EUR 246.1m | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months2025-01-01 to 2025-12-31 | EUR 5.8m | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2025-01-01 to 2025-12-31 | −EUR 336.1m | ifrs-full:ProfitLoss |
| Diluted EPS | 12 months2025-01-01 to 2025-12-31 | −EUR 4.83 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2025-01-01 to 2025-12-31 | −EUR 4.83 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2025-01-01 to 2025-12-31 | −EUR 161.1m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2025-01-01 to 2025-12-31 | EUR 142.0k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2025-12-31 | EUR 516.7m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2025-12-31 | EUR 551.2m | ifrs-full:CurrentAssets |
| Total assets | At period end2025-12-31 | EUR 584.3m | ifrs-full:Assets |
| Current liabilities | At period end2025-12-31 | EUR 63.0m | ifrs-full:CurrentLiabilities |
| Shareholders' equity | At period end2025-12-31 | EUR 455.2m | ifrs-full:Equity |
| Shares outstanding | At period end2025-12-31 | 78,536,412 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001956827-26-000012. Last ingested by Listed: Oct 24, 2026, 15:16 ET. Listed shows no prices and gives no investment advice.